Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Fengting Yu; Qun Li; Linghang Wang; Hongxin Zhao; Hao Wu; Siyuan Yang; Yunxia Tang; Jiang Xiao; Fujie Zhang

doi:10.2147/PGPM.S345797

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Pharmgenomics Pers Med. 2022 Mar 10:15:195-203. doi: 10.2147/PGPM.S345797. eCollection 2022.

Authors

Fengting Yu^#^{1

2}, Qun Li^#^{1

2}, Linghang Wang^{1

2}, Hongxin Zhao^{1

2}, Hao Wu³, Siyuan Yang^{1

2}, Yunxia Tang^{1

2}, Jiang Xiao^{1

2}, Fujie Zhang^{1

2}

Affiliations

¹ Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
² Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China.
³ Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.

^# Contributed equally.

Abstract

Introduction: Integrase strand transfer inhibitors (INSTIs) are important drugs that are currently used as the first line treatment for HIV-1 patients. The aim of this study was to characterize HIV-1 INSTI mutations among ART-naive patients in Beijing from 2019-2021.

Methods: 865 ART-naive patients were enrolled in this study between January 2019 and June 2021 in Beijing. The amplification of the entire pol gene containing the reverse transcriptase, protease and integrase regions was performed using a validated In-house SBS method. HIV-1 subtypes and circulating recombinant forms (CRFs) were determined using the COMET online tool (http://comet.retrovirology.lu). Stanford HIV-1 drug resistance database (HIVdb version 8.9) was used to analyze the mutations.

Results: 865 HIV-1 pol sequences were successfully amplified and sequenced. Among them, no major INSTI-related mutations were identified, but 12 polymorphic accessory mutations were found. Two patients have E138A and G163R mutations respectively and both could cause low-level resistance to RAL and EVG. Furthermore, one patient having S230R mutation resulted in low-level resistance to RAL, EVG, DTG and BIC.

Conclusion: The prevalence of INSTIs mutations remains low, which demonstrated that INSTIs have good applicability currently in our city. Nevertheless, it is very important to monitor the INSTI-related mutations in Beijing.

Keywords: Beijing; HIV-1; genotype; integrase strand transfer inhibitor; pre-treatment drug resistance mutation.

Grants and funding

This work was funded in part by Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20191802) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX202126).